Despite modern software advances, creating an overarching clinical data management strategy is extremely challenging. We speak to clinical data experts about the benefits of adapting data standards and the risks involved if users choose to ignore them.
Go deeper with GlobalData
We also look into the UK Government’s controversial plan to open up clinical patient data to the pharmaceutical industry and cast a critical eye over its opportunities and dangers.
Moreover, we investigate the risks posed by missing or inadequate data, explore the rise of collaborative clinical data software and delve into cloud computing to find out whether this technology can streamline data for the drug industry to make information more accessible.
Read the latest issue for free
See Also:
In this issue
The Big Picture
Despite modern software advances, creating an overarching clinical data management strategy remains challenging. Octagon Research’s David Evans and Barry Cohen talk to Chris Lo about the benefits of adopting data standards.
Read the full article.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataOut of Sight
Unpublished clinical trial data is a persistent problem which stems from the pursuit of safe, evidence-based medicine. Chris Lo investigates the dangers of missing trial data and asks how a more transparent system can be achieved in the future.
Read the full article.
Opening up the NHS
The UK Government’s proposal to open up public healthcare data to pharma companies could boost innovation in the country. Elisabeth Fischer investigates the privacy and organisational concerns that need to be addressed first.
Read the full article.
One for All
As trial data grows in volume and complexity, researchers are finding the load increasingly unmanageable. Elly Earls explores how interoperable software systems could help the sector to stay on top of the data flood.
Read the full article.
Clouds of Change
Excessive data may be to blame for low productivity rates in the drug industry. Sarah Blackman looks at how cloud computing can streamline data and speed up drug discovery.
Read the full article.
Mobile Revolution
Big Pharma is starting to embrace mobile technology, but it still needs to tackle data and structural challenges before it can truly reap the benefits of wireless devices. Elisabeth Fischer reports on recent progress.
Read the full article
Next Issue: Special Delivery
Nanotechnology has emerged as one of the most exciting new drug delivery technologies. We explore two potential applications in cancer treatment: a chemotherapy drug loaded with nanobubbles, which experts have found to be 30 times more lethal to cancer cells, as well as a star-shaped gold nanoparticle that can deliver drugs directly to the nucleus of a cancer cell.
We also look at other breakthroughs, including an externally controlled wireless device that can be propelled through the blood and a delivery method using 3D superhydrophobic materials, which could control drug absorption over a three-month period, and investigate the science behind new class of highly selective targeted therapeutics known as Accurins, which promise a higher level of accuracy in drug delivery.
Digital Magazine FAQ
The digital magazine is viewable on any computer with Flash Player installed. It is also viewable on mobile devices, iPhones and iPads, although some features and videos may be disabled.
View the archive of back issues.
